Last Posted: Oct 04, 2019
- A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
L Sun et al, JAMA Oncology, October 3, 2019 - After a Breast Cancer Diagnosis, Men May Be More Likely to Die than Women
NCI, October 2, 2019 - Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
Gail Mitchell H et al. Journal of the National Cancer Institute 2018 110(9) 994-1002 - New name for breast-cancer syndrome could help to save lives.
Pritchard Colin C et al. Nature 2019 571(7763) 27-29 - ---Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy.
Sjöström Martin et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep - A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management.
Kunst Natalia R et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Oct 22(10) 1102-1110 - Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Farkas Amy et al. Journal of women's health (2002) 2019 Sep - Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
Wei Xiaoxia et al. Clinical drug investigation 2019 Sep - Hereditary breast cancer: screening and risk reducing surgery.
Renzulli Matteo et al. Gland surgery 2019 Sep 8(Suppl 3) S142-S149 - Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.
Brédart Anne et al. BMJ open 2019 Sep 9(9) e029926
No comments:
Post a Comment